UroGen Pharma Ltd. financial data

Symbol
URGN on Nasdaq
Industry
Pharmaceutical Preparations
Location
9 Ha'ta'asiya St, Ra'anana, Israel
State of incorporation
Israel
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 703 % +56.1%
Quick Ratio 21.6 % +4.25%
Debt-to-equity -830 % -284%
Return On Equity 388 % +263%
Return On Assets -53.2 % +42.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 42.1M shares +39.1%
Common Stock, Shares, Outstanding 41.2M shares +75.2%
Entity Public Float 190M USD +31.2%
Common Stock, Value, Issued 112K USD +75%
Weighted Average Number of Shares Outstanding, Basic 36.8M shares +56.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 85M USD +17.2%
Cost of Revenue 8.61M USD -4.24%
Research and Development Expense 52.4M USD +1.5%
Operating Income (Loss) -79.7M USD -5.14%
Nonoperating Income (Expense) 686K USD +53.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -110M USD -1.93%
Income Tax Expense (Benefit) 3.94M USD +167%
Net Income (Loss) Attributable to Parent -114M USD -4.16%
Earnings Per Share, Basic -3.1 USD/shares +34.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 220M USD +993%
Cash, Cash Equivalents, and Short-term Investments 241M USD +336%
Accounts Receivable, after Allowance for Credit Loss, Current 17.4M USD +12.3%
Inventory, Net 7.44M USD +49.2%
Assets, Current 279M USD +243%
Property, Plant and Equipment, Net 580K USD -36.3%
Operating Lease, Right-of-Use Asset 1.25M USD -40.7%
Other Assets, Noncurrent 673K USD -76.1%
Assets 282M USD +196%
Accounts Payable, Current 8.32M USD +78.5%
Employee-related Liabilities, Current 6.85M USD +1.9%
Liabilities, Current 34.2M USD +27.9%
Operating Lease, Liability, Noncurrent 425K USD -64.8%
Liabilities 252M USD +7.59%
Accumulated Other Comprehensive Income (Loss), Net of Tax -31K USD +79.9%
Retained Earnings (Accumulated Deficit) -745M USD -18%
Stockholders' Equity Attributable to Parent 30.3M USD
Liabilities and Equity 282M USD +196%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -31.7M USD -23%
Net Cash Provided by (Used in) Financing Activities 54.7M USD +8046%
Net Cash Provided by (Used in) Investing Activities 13.5M USD +116%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 41.2M shares +75.2%
Common Stock, Par or Stated Value Per Share 0.01 ILS/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 36.4M USD
Deferred Tax Assets, Valuation Allowance 144M USD +10.8%
Operating Lease, Liability 1.22M USD -42.4%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -113M USD -3.95%
Lessee, Operating Lease, Liability, to be Paid 1.31M USD -44.7%
Property, Plant and Equipment, Gross 4.73M USD +5.35%
Operating Lease, Liability, Current 796K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 57K USD -93%
Lessee, Operating Lease, Liability, to be Paid, Year One 817K USD -11.5%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 88K USD -64.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 58K USD -92.6%
Deferred Tax Assets, Operating Loss Carryforwards 104M USD +7.4%
Unrecognized Tax Benefits 3.2M USD +6.67%
Lessee, Operating Lease, Liability, to be Paid, Year Four 49K USD
Operating Lease, Payments 277K USD -5.78%
Depreciation, Depletion and Amortization 608K USD -34.3%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 11.2M USD +19.7%